Differential effects of SARS-CoV-2 variants on central nervous system cells and blood–brain barrier functions

[1]  Hideyuki Okano,et al.  The original strain of SARS-CoV-2, the Delta variant, and the Omicron variant infect microglia efficiently, in contrast to their inability to infect neurons: Analysis using 2D and 3D cultures , 2023, Experimental Neurology.

[2]  Loic A. Royer,et al.  Neuropilin-1 Mediates SARS-CoV-2 Infection of Astrocytes in Brain Organoids, Inducing Inflammation Leading to Dysfunction and Death of Neurons , 2022, mBio.

[3]  C. Yasuda,et al.  Morphological, cellular, and molecular basis of brain infection in COVID-19 patients , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Taquet,et al.  Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients , 2022, The Lancet Psychiatry.

[5]  Madeline G. Andrews,et al.  Tropism of SARS-CoV-2 for human cortical astrocytes , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Kivipelto,et al.  Changes in cognitive functioning after COVID‐19: A systematic review and meta‐analysis , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[7]  Thomas E. Nichols,et al.  SARS-CoV-2 is associated with changes in brain structure in UK Biobank , 2022, Nature.

[8]  Jaemyun Lyu,et al.  SARS-CoV-2 Infection of Microglia Elicits Pro-inflammatory Activation and Apoptotic Cell Death , 2022, bioRxiv.

[9]  H. Gao,et al.  SARS-CoV-2 crosses the blood–brain barrier accompanied with basement membrane disruption without tight junctions alteration , 2021, Signal Transduction and Targeted Therapy.

[10]  G. E. Umanah,et al.  SARS-CoV-2 Neuronal Invasion and Complications: Potential Mechanisms and Therapeutic Approaches , 2021, The Journal of Neuroscience.

[11]  C. Swanton,et al.  Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination , 2021, The Lancet.

[12]  A. Saghatelyan,et al.  SARS-CoV-2 spike protein induces brain pericyte immunoreactivity in absence of productive viral infection , 2021, bioRxiv.

[13]  W. Banks,et al.  Interactions of SARS-CoV-2 with the Blood–Brain Barrier , 2021, International journal of molecular sciences.

[14]  Ben M. Maoz,et al.  Effect of SARS-CoV-2 proteins on vascular permeability , 2021, bioRxiv.

[15]  C. Swanton,et al.  Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains , 2021, bioRxiv.

[16]  M. Toborek,et al.  Expression of SARS-CoV-2-related Receptors in Cells of the Neurovascular Unit: Implications for HIV-1 Infection , 2021, Journal of Neuroinflammation.

[17]  J. Haas,et al.  Lack of Evidence of Angiotensin-Converting Enzyme 2 Expression and Replicative Infection by SARS-CoV-2 in Human Endothelial Cells , 2021, Circulation.

[18]  Zhaohui Zheng,et al.  CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells , 2020, Signal Transduction and Targeted Therapy.

[19]  A. Gorbalenya,et al.  A nidovirus perspective on SARS-CoV-2 , 2020, Biochemical and Biophysical Research Communications.

[20]  M. Tremblay,et al.  Neuropathobiology of COVID-19: The Role for Glia , 2020, Frontiers in Cellular Neuroscience.

[21]  A. Helenius,et al.  Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity , 2020, Science.

[22]  G. Millet,et al.  Mitochondria – in the crossfire of SARS-CoV-2 and immunity , 2020, iScience.

[23]  V. Bansal,et al.  A Single-Cell RNA Expression Map of Human Coronavirus Entry Factors , 2020, Cell Reports.

[24]  G. Chaubey,et al.  Decoding SARS-CoV-2 hijacking of host mitochondria in COVID-19 pathogenesis , 2020, American journal of physiology. Cell physiology.

[25]  M. Inglese,et al.  Acute disseminated encephalomyelitis after SARS-CoV-2 infection , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[26]  J. Loscalzo,et al.  Metabolic Responses to Reductive Stress , 2020, Antioxidants & redox signaling.

[27]  K. Kim,et al.  What Is COVID-19? , 2020, Frontiers for Young Minds.

[28]  L. French,et al.  The Spatial and Cell-Type Distribution of SARS-CoV-2 Receptor ACE2 in the Human and Mouse Brains , 2020, bioRxiv.

[29]  M. Tremblay,et al.  HIV‐1 infection and latency‐reversing agents bryostatin‐1 and JQ1 disrupt amyloid beta homeostasis in human astrocytes , 2020, Glia.

[30]  N. Enomoto,et al.  A first case of meningitis/encephalitis associated with SARS-Coronavirus-2 , 2020, International Journal of Infectious Diseases.

[31]  K. Hashimoto,et al.  Nervous system involvement after infection with COVID-19 and other coronaviruses , 2020, Brain, Behavior, and Immunity.

[32]  Lingyan Zhou,et al.  Sars-Cov-2: Underestimated damage to nervous system , 2020, Travel Medicine and Infectious Disease.

[33]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[34]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[35]  Denis Gris,et al.  Astrocytes Maintain Glutamate Homeostasis in the CNS by Controlling the Balance between Glutamate Uptake and Release , 2019, Cells.

[36]  Alexis M. Kalergis,et al.  Neurologic Alterations Due to Respiratory Virus Infections , 2018, Front. Cell. Neurosci..

[37]  P. Uchil,et al.  Analysis of Cell Viability by the MTT Assay. , 2018, Cold Spring Harbor protocols.

[38]  A. Abramov,et al.  Role of mitochondrial ROS in the brain: from physiology to neurodegeneration , 2018, FEBS letters.

[39]  M. Tremblay,et al.  Contrasting effect of the latency-reversing agents bryostatin-1 and JQ1 on astrocyte-mediated neuroinflammation and brain neutrophil invasion , 2017, Journal of Neuroinflammation.

[40]  M. Tremblay,et al.  HIV-1 Latency-Reversing Agents Prostratin and Bryostatin-1 Induce Blood–Brain Barrier Disruption/Inflammation and Modulate Leukocyte Adhesion/Transmigration , 2017, The Journal of Immunology.

[41]  E. Chang,et al.  Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse , 2016, Neuron.

[42]  R. Keep,et al.  Junctional proteins of the blood-brain barrier: New insights into function and dysfunction , 2016, Tissue barriers.

[43]  B. Frey,et al.  Disruption in the Blood-Brain Barrier: The Missing Link between Brain and Body Inflammation in Bipolar Disorder? , 2015, Neural plasticity.

[44]  A. Hajeer,et al.  Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV) , 2015, Infection.

[45]  A. Traweger,et al.  “You Shall Not Pass”—tight junctions of the blood brain barrier , 2014, Front. Neurosci..

[46]  Z. Memish,et al.  Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia , 2014, International Journal of Infectious Diseases.

[47]  D. Broadhurst,et al.  Rapid inflammasome activation in microglia contributes to brain disease in HIV/AIDS , 2014, Retrovirology.

[48]  Alain Le Coupanec,et al.  Neuroinvasive and Neurotropic Human Respiratory Coronaviruses: Potential Neurovirulent Agents in Humans , 2014, Advances in experimental medicine and biology.

[49]  J. Privratsky,et al.  PECAM-1: regulator of endothelial junctional integrity , 2014, Cell and Tissue Research.

[50]  R. Ransohoff,et al.  Development, maintenance and disruption of the blood-brain barrier , 2013, Nature Medicine.

[51]  M. Desforges,et al.  Novel Treatment with Neuroprotective and Antiviral Properties against a Neuroinvasive Human Respiratory Virus , 2013, Journal of Virology.

[52]  Be'eri Niego,et al.  Improved method for the preparation of a human cell-based, contact model of the blood-brain barrier. , 2013, Journal of visualized experiments : JoVE.

[53]  P. Couraud,et al.  Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation , 2012, Fluids and Barriers of the CNS.

[54]  P. Couraud,et al.  Guanine Nucleotide-Binding Protein Gαi2: A New Partner of Claudin-5 that Regulates Tight Junction Integrity in Human Brain Endothelial Cells , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[55]  M. Desforges,et al.  Glutamate Excitotoxicity Is Involved in the Induction of Paralysis in Mice after Infection by a Human Coronavirus with a Single Point Mutation in Its Spike Protein , 2011, Journal of Virology.

[56]  Z. Qin,et al.  Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases , 2009, Acta Pharmacologica Sinica.

[57]  Bo Zhang,et al.  Multiple organ infection and the pathogenesis of SARS , 2005, The Journal of experimental medicine.

[58]  H. Doerr,et al.  Molecular and Biological Characterization of Human Monoclonal Antibodies Binding to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome Coronavirus , 2005, Journal of Virology.

[59]  L. Tsai,et al.  Neuromuscular disorders in severe acute respiratory syndrome. , 2004, Archives of neurology.

[60]  J. Fleming,et al.  Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[61]  J. Newcombe,et al.  Neuroinvasion by Human Respiratory Coronaviruses , 2000, Journal of Virology.

[62]  P. Talbot,et al.  Human coronavirus gene expression in the brains of multiple sclerosis patients , 1992, Virology.

[63]  M. Reunanen,et al.  Antibodies to coronaviruses OC43 and 229E in multiple sclerosis patients , 1982, Neurology.

[64]  M. Velasco,et al.  Excitotoxicity: An Organized Crime at The Cellular Level , 2017 .

[65]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..